Amplyx laid out a promising path to a pivotal antifungal drug trial, and now Pfizer is scooping it all up in a buyout

Just 9 months after Amplyx laid out promising Phase II data for their lead antifungal, Pfizer is stepping out of the syndicate that backed …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Am­plyx laid out a promis­ing path to a piv­otal an­ti­fun­gal drug tri­al, and now Pfiz­er is scoop­ing it all up in a buy­out